This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
DOW vs. DD: Which Chemical Giant Deserves a Spot in Your Portfolio?
by Anindya Barman
Dow tackles weak demand with cost cuts and cash actions, while DuPont gains from acquisitions in healthcare and innovation.
DuPont Achieves 100% Renewable Electricity in EU Operations
by Zacks Equity Research
DD hits 100% renewable electricity for EU operations, marking a major step toward its 2050 net-zero emissions goal using RECs and solar installations.
DuPont Launches AmberChrom TQ1 Resin for Biopharma Applications
by Zacks Equity Research
DD launches AmberChrom TQ1 resin, boosting oligonucleotide and peptide purification with high capacity, purity, and scalability.
DuPont's Q1 Earnings Surpass Estimates, Revenues Increase Y/Y
by Zacks Equity Research
DD continues to benefit from sustained strength in the electronics markets, along with robust demand in the healthcare and water end markets.
DuPont de Nemours (DD) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
DuPont de Nemours (DD) delivered earnings and revenue surprises of 8.42% and 0.85%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
DuPont Gears Up for Q1 Earnings: What's in the Offing for the Stock?
by Zacks Equity Research
DD is expected to have benefited from its innovation-driven investment, productivity actions and acquisitions amid pricing pressures in Q1.
Tronox (TROX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Tronox (TROX) delivered earnings and revenue surprises of -850% and 3.08%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Chemours (CC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DuPont de Nemours (DD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
DuPont de Nemours (DD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LyondellBasell (LYB) Q1 Earnings Miss Estimates
by Zacks Equity Research
LyondellBasell (LYB) delivered earnings and revenue surprises of -8.33% and 1.10%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?